Palifermin

Palifermin is the recombinant human keratinocyte growth factor (KGF). Palifermin induces cells growth. Palifermin shows antimucotoxic. Palifermin can be used to decrease the oral mucosal injury induced by cytotoxic therapy[1][2][3].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Palifermin (0-100 ng/mL; 48 h) stimulates the growth of TE-8, TE-11 cells[1]. Cell Proliferation Assay[1] Cell Line: TE-1, TE-8, TE-11 cells Concentration: 0, 1, 10 100 ng/mL Incubation Time: 48 h Result: Increased the proliferation for TE-8, TE-11 cells and did not stimulate the growth of TE-1 cells.

Palifermin (10 mg/kg for single dose or 3 mg/kg for 3 times; daily for 3 days) reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats[2]. Palifermin (5 mg/kg; s.c.) shows effectiveness on oral mucositis induced by fractionated irradiation[3]. Animal Model: DA rats[2] Dosage: 10 mg/kg for single dose or 3 mg/kg for 3 times Administration: Daily for 3 days prior to chemotherapy treatment Result: Reduced diarrhea and increased survival following Irinotecan treatment. Animal Model: Mouse with 5*3 Gy/week irradiation (tongue model)[3] Dosage: 5 mg/kg Administration: S.c; at -3, +4, +11 days or +4, +11, +18 days or -3, +4, +11, +18 days Result: Showed effectiveness on oral mucositis (mouse) induced by fractionated irradiation.

[1]. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8.

[2]. Yoshino M, et al. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol. 2007 Oct;31(4):721-8.

[3]. Dörr W, et al. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol. 2005 Apr;75(1):99-105.